Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

271
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
271
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

235
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
235
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

389
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
389
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

241
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
241
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

235
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
235
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

297
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
297

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Sleeve Gastrectomy Versus Intensive Lifestyle Modifications With Obesity Management Medications on BMI Trajectory and Target Attainment: A Prospective Matched Cohort Study.

Diabetes, obesity & metabolism·2026
Same author

Endoluminal device induces insulin sensitivity and greater weight control than semaglutide in pigs.

Gut·2026
Same author

Correction: Post-Operative Safety Outcomes and 5-Year Healthcare Utilisation After Bariatric Surgery vs. Other Elective Types of Surgical Treatments - A Retrospective Observational Cohort Study.

Obesity surgery·2026
Same author

Post-Operative Safety Outcomes and 5-Year Healthcare Utilisation After Bariatric Surgery vs. Other Elective Types of Surgical Treatments - A Retrospective Observational Cohort Study.

Obesity surgery·2026
Same author

Impact of overweight and obesity on fasting insulin secretion in men and women without diabetes: effect sizes and mechanisms.

Diabetologia·2025
Same author

Accompanying editorial for the article "Extracellular vesicle signature is associated with cardio-metabolic improvement in obese patients after bariatric surgery".

European journal of preventive cardiology·2025
Same journal

Plasma oxytocin, early predictor of transient postoperative arginine vasopressin deficiency.

The Journal of clinical endocrinology and metabolism·2026
Same journal

Is diagnosis of Cushing's disease moving beyond Bilateral inferior petrosal sinus sampling?

The Journal of clinical endocrinology and metabolism·2026
Same journal

Can Machine Learning Transform the Diagnostic Approach to Congenital Disorders of Adrenal Steroidogenesis?

The Journal of clinical endocrinology and metabolism·2026
Same journal

Children's neurodevelopment at school age after hysterosalpingography with iodinated contrast: a cohort study.

The Journal of clinical endocrinology and metabolism·2026
Same journal

Bone phenotype of patients with genetic forms of lipodystrophy: a systematic review of literature.

The Journal of clinical endocrinology and metabolism·2026
Same journal

The Extra X Chromosome and Autoimmune Susceptibility in Klinefelter Syndrome.

The Journal of clinical endocrinology and metabolism·2026
See all related articles

Related Experiment Video

Updated: Aug 28, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

10.7K

New Horizons: Emerging Antidiabetic Medications.

Geltrude Mingrone1,2,3, Lidia Castagneto-Gissey4, Stefan R Bornstein3,5

  • 1Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome 00169, Italy.

The Journal of Clinical Endocrinology and Metabolism
|September 15, 2022
PubMed
Summary
This summary is machine-generated.

New diabetes drugs show promise for treating type 2 diabetes (T2D) by improving blood sugar control and promoting weight loss. These advanced therapies also offer cardiovascular and kidney benefits, addressing multiple metabolic defects.

Keywords:
GLP1 receptor agonistantidiabetic medicationsgliflozinincretinstype 2 diabetes

More Related Videos

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.3K
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

94.7K

Related Experiment Videos

Last Updated: Aug 28, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

10.7K
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.3K
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

94.7K

Area of Science:

  • Endocrinology and Metabolism
  • Pharmacology

Background:

  • Therapeutic options for diabetes have significantly expanded since insulin's discovery.
  • Type 2 diabetes (T2D) management requires addressing hyperglycemia, insulin resistance, and obesity.
  • Emerging antidiabetic drugs offer enhanced efficacy and address multiple metabolic defects.

Approach:

  • Review of current and pipeline medications for type 1 diabetes and T2D.
  • Evaluation of antihyperglycemic effects, weight management, and cardiovascular/renal outcomes.
  • Analysis of novel drug classes, including GLP-1 RAs and dual GLP1/GIP RAs.

Key Points:

  • Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP1/GIP RAs demonstrate significant antihyperglycemic and weight-loss effects.
  • SGLT2 inhibitors show benefits in reducing cardiovascular disease and diabetic nephropathy risk.
  • Pipeline drugs aim to target multiple T2D pathologies, including hyperglycemia, insulin resistance, and obesity.

Conclusions:

  • The diabetes drug pipeline holds significant promise for improved T2D treatment.
  • Novel therapies offer comprehensive metabolic benefits beyond glycemic control.
  • Future medications are expected to provide superior outcomes for cardiovascular and renal complications in diabetic patients.